Literature DB >> 34082687

Alirocumab in Post ACS Patients - Saving Lives at a Premium.

Melvin George1, Luxitaa Goenka1.   

Abstract

Entities:  

Keywords:  Alirocumab; ODYSSEY outcome study; PCSK inhibitors; major adverse cardiac events; mortality

Mesh：

Substances：

Year:  2022        PMID： 34082687      PMCID： PMC9241115          DOI： 10.2174/1573403X17666210603111158

Source DB:  PubMed          Journal:  Curr Cardiol Rev        ISSN： 1573-403X


× No keyword cloud information.
  7 in total

1.  Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.

Authors:  Deepak L Bhatt; Andrew H Briggs; Shelby D Reed; Lieven Annemans; Michael Szarek; Vera A Bittner; Rafael Diaz; Shaun G Goodman; Robert A Harrington; Keiko Higuchi; Florence Joulain; J Wouter Jukema; Qian H Li; Kenneth W Mahaffey; Robert J Sanchez; Matthew T Roe; Renato D Lopes; Harvey D White; Andreas M Zeiher; Gregory G Schwartz; Ph Gabriel Steg
Journal:  J Am Coll Cardiol       Date:  2020-05-12       Impact factor: 24.094

2.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

Review 3.  Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.

Authors:  Parth Shah
Journal:  Curr Cardiol Rep       Date:  2018-05-19       Impact factor: 2.931

4.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Authors:  Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Deepak L Bhatt; Vera A Bittner; Rafael Diaz; Jay M Edelberg; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Guillaume Lecorps; Kenneth W Mahaffey; Angèle Moryusef; Robert Pordy; Kirby Quintero; Matthew T Roe; William J Sasiela; Jean-François Tamby; Pierluigi Tricoci; Harvey D White; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2018-11-07       Impact factor: 91.245

5.  Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.

Authors:  Rafael Diaz; Qian H Li; Deepak L Bhatt; Vera A Bittner; Marie T Baccara-Dinet; Shaun G Goodman; J Wouter Jukema; Takeshi Kimura; Alexander Parkhomenko; Robert Pordy; Željko Reiner; Matthew T Roe; Michael Szarek; Hung-Fat Tse; Harvey D White; Doron Zahger; Andreas M Zeiher; Gregory G Schwartz; Ph Gabriel Steg
Journal:  Eur J Prev Cardiol       Date:  2020-07-27       Impact factor: 7.804

6.  Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.

Authors:  Max Korman; Torbjørn Wisløff
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2018-01-01

Review 7.  Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.

Authors:  Courtney A Henry; Ronald A Lyon; Hua Ling
Journal:  Vasc Health Risk Manag       Date:  2016-04-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.